Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) has announced the replenishment of its New Employee Inducement Award Plan with 471,833 shares of common stock, effective June 16, 2020. This addition is on top of 500,000 shares registered previously on May 28, 2021. The plan aims to grant equity awards to new hires or former employees, serving as an inducement for their employment as per Nasdaq Listing Rule 5635(c)(4).
Jaguar focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) announces a dinner event for U.S. veterinary oncologists on April 12, 2022, in Puerto Vallarta, Mexico, coinciding with the Veterinary Cancer Society (VCS) Mid-Year Conference. The dinner will focus on chemotherapy-induced diarrhea (CID) treatment in dogs, featuring a private chef and entertainment. Canalevia-CA1 (crofelemer), the first FDA conditionally approved treatment for CID in dogs, will be showcased at the conference. The VCS Mid-Year Conference runs from April 9-12, 2022, at the Marriott Puerto Vallarta Resort & Spa.
Jaguar Health, Inc. has appointed Pravin Chaturvedi, PhD, as Chief Scientific Officer and Chair of the Scientific Advisory Board. Dr. Chaturvedi, with over 30 years in the pharmaceutical industry, will lead two key crofelemer pipeline development activities over the next 12-15 months. These include the Phase 3 OnTarget trial for cancer therapy-related diarrhea and collaborations for rare diseases like short bowel syndrome. Both initiatives aim to expand patient access and enhance Jaguar's market position, with completion expected soon.
Jaguar Health has entered a strategic agreement with Quadri Pharmaceuticals Store granting exclusive promotional, commercialization, and distribution rights for crofelemer in multiple Middle Eastern countries, including Saudi Arabia and the UAE. This agreement covers human indications approved in the U.S., specifically targeting HIV-related and cancer therapy-related diarrhea. The partnership aims to enhance access to crofelemer, which is currently undergoing a pivotal Phase 3 clinical trial. This initiative is crucial due to the rising HIV statistics in the region, highlighting the growing demand for effective treatments.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a recorded investor webcast on March 14, 2022, sharing company updates and 2021 financial results. Key initiatives include the ongoing OnTarget Phase 3 clinical trial for crofelemer, focused on preventing cancer therapy-related diarrhea. The company reported Mytesi net revenue of approximately $2.1 million in Q4 2021, a significant increase of 230% from Q3 2021. Additionally, Jaguar received FDA conditional approval in December 2021 for Canalevia™-CA1 treating chemotherapy-induced diarrhea in dogs.
Jaguar Health provided a comprehensive update on its progress during 2021, highlighting critical milestones in the development of its plant-based drug pipeline. Key achievements include the ongoing OnTarget Phase 3 clinical trial for crofelemer, FDA conditional approval for Canalevia-CA1 for chemotherapy-induced diarrhea in dogs, and a significant revenue increase for Mytesi, which saw net revenues of approximately $2.1 million in Q4 2021, marking a 230% increase from Q3 2021. Despite these advances, the company reported a substantial net loss of $52.6 million for 2021.
Jaguar Health (NASDAQ:JAGX) has announced an investor webcast scheduled for March 14, 2022, at 8:30 AM ET to discuss its Q4 2021 financials and corporate updates. The company plans to file its Annual Report on March 11, 2022, for the fiscal year ending December 31, 2021. Jaguar focuses on developing plant-based, non-opioid prescription medicines for gastrointestinal distress. Their crofelemer drug candidate is being evaluated in a pivotal Phase 3 clinical trial. For more information, visit jaguar.health.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced a treatment forum for veterinarians on March 6, 2022, during the Western Veterinary Conference in Las Vegas. The forum will discuss chemotherapy-induced diarrhea (CID) in dogs and feature noted oncologist Dr. Craig A. Clifford. Canalevia-CA1, the first FDA conditionally approved treatment for CID in dogs, will be highlighted. Registration is open to U.S. veterinarians and media via the Canalevia website. The event aims to address the unmet need for effective CID treatments as over half of veterinarians report CID impacting chemotherapy plans.
Jaguar Health (NASDAQ:JAGX) has applied for MUMS designation from the FDA for Canalevia™-CA2, aimed at treating exercise-induced diarrhea (EID) in dogs. This follows the conditional approval of Canalevia™-CA1 for chemotherapy-induced diarrhea (CID) in December 2021.
The MUMS designation would provide incentives for drug development, including potential federal grants and seven years of marketing exclusivity following conditional approval. This marks a significant step in expanding treatment options for veterinary care.
Jaguar Health (NASDAQ:JAGX) announced that its Italian subsidiary, Napo Therapeutics, has received Small and Medium Enterprise (SME) designation from the European Medicines Agency (EMA). This status provides financial incentives and support for the regulatory process, crucial for advancing the availability of crofelemer in Europe for treating rare diseases. SME companies have shown a high success rate of 89% for marketing authorizations, with nearly 20% of human medicines recommended for authorization in 2020 targeting rare diseases.